ruxolitinib phosphate (Jakavi®) accepted for use within NHSScotland

Source:
Scottish Medicines Consortium - SMC
Publisher:
Scottish Medicines Consortium
Publication date:
09 December 2019

Abstract

The SMC recommends ruxolitinib for the treatment of adults with polycythaemia vera who are resistant to or intolerant of hydroxyurea (hydroxycarbamide), based on data from 2 phase III RCTs in patients with/without splenomegaly who were resistant or intolerant of hydroxycarbamide.